Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Gynecology | Internal Medicine | Nursing | Oncology | Pathology | Journal

Back to Journal Articles

HPV DNA Testing Leads to Early Detection of Cervical Cancer

Last Updated: December 15, 2011.

 

Lower detection of cervical intraepithelial lesions, cervical cancer during second HPV DNA screen

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Human papillomavirus DNA testing at a first screening results in detection of fewer cases of cervical intraepithelial neoplasia (CIN) grade 2 or worse, CIN grade 3 or worse, and cervical cancer at a second screening five years later, according to a study published online Dec. 15 in The Lancet Oncology.

THURSDAY, Dec. 15 (HealthDay News) -- Human papillomavirus (HPV) DNA testing at a first screening results in detection of fewer cases of cervical intraepithelial neoplasia (CIN) grade 2 or worse, CIN grade 3 or worse, and cervical cancer at a second screening five years later, according to a study published online Dec. 15 in The Lancet Oncology.

Dorien C. Rijkaart, M.D., from the VU University Medical Center in Amsterdam, Netherlands, and colleagues investigated whether HPV DNA testing in a first screen impacted the detection of CIN grade 2 or worse, CIN grade 3 or worse, and cervical cancer in a second screening five years later. Women (aged 29 to 56 years) were randomized to HPV DNA and cytology co-testing (intervention) or to cytology alone (control) at the first screen, while HPV DNA and cytology co-testing was done for both groups at the second screening.

The investigators found that, at the second screen, CIN grade 3 or worse and cervical cancer were significantly less common in the intervention than control group. In the baseline round, significantly more cases of CIN grade 2 or worse were detected in the intervention group. At the second screen, non-HPV16-positive CIN grade 3 or worse detection did not differ significantly between the groups (P = 1.0), but fewer HPV16-positive CIN grade 3 or worse were detected in the intervention group. Cumulative detection of CIN grade 2 or worse and CIN grade 3 or worse was not significantly different between study groups (P = 0.631).

"Our results lend support to the use of HPV DNA testing for all women aged 29 years and older," the authors write.

Several authors disclosed financial relationships with the pharmaceutical industry. Several authors hold patents pertaining to HPV detection and cervical cancer.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.


Previous: High Prevalence of Obesity Found Among Adults in Spain Next: Statins Lower Death Risk in Adults Hospitalized With Flu

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.